All In Biotech

Investigational drug · Phase 2

SKB315

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastroesophageal Junction Adenocarcinoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: May 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "SKB315"

First trial start

2026

Jun 30, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "SKB315", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Gastroesophageal Junction Adenocarcinoma

Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "SKB315" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Gastroesophageal Junction Adenocarcinoma

  • CadonilimabAK104Phase 331 trials

    Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • AZD0901Sonesitatug vedotin, CMG901Phase 36 trials

    AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma

  • BudigalimabABBV-181Phase 36 trials

    AbbVie · Hepatocellular Carcinoma, Non Small Cell Lung Carcinoma, c-MET

  • QLS31905Phase 35 trials

    Qilu Pharmaceutical Co., Ltd. · Advanced Solid Tumor, CLDN18.2-positive Advanced Biliary Tract Cancer, Gastric Adenocarcinoma

  • SHR-A1904Phase 35 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Biliary Tract Cancer, Advanced Solid Tumors

  • IBI343Arcotatug TavatecanPhase 34 trials

    Innovent Biologics (Suzhou) Co. Ltd. · CLDN18.2 Positive, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Primary Gastric Adenocarcinoma

  • ASKB589Phase 33 trials

    AskGene Pharma, Inc. · Gastric Cancer, Gastroesophageal Cancer (GC), Malignant Solid Tumor

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.